Statins and HIV: Beyond the metabolic and cardiovascular benefit [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 4, 2005, Pages 503-504

  Corrales Medina, Vicente F ^a   Carpio, Freddy Del ^a   Concha, Ronald ^a   Symes, Stephen ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEINASE INHIBITOR;

CARDIOVASCULAR RISK; CYTOTOXIC T LYMPHOCYTE; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; RISK FACTOR; TH1 CELL; TH2 CELL;

EID: 22344445602     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000170531.73031.f7     Document Type: Letter

References (12)

1. Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr. 2005;38:115-123.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
3. Hulgan T, Sterling TR, Daugherty J, et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr. 2005;38:277-282.
4. Shimada K, Miyauchi K, Daida H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation. 2004;109(Suppl):e213-e214.
5. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003;93:948-956.
6. Kinlay S, Schwartz GG, Olsson AG, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.
7. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.
8. Hori A, Kanda Y, Goyama S, et al. Japan Hematology and Oncology Clinical Study Group. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation. 2005;79:372-374.
9. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother. 2001;12:133-150.
10. Imami N, Pires A, Hardy G, et al. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol. 2002;76:9011-9023.
11. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis. 2004;4:397-413.
12. Narayan YS, Hawley N, Giguere P, et al. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials. 2003;4:164-169.